当前位置:
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-11-18 , DOI: 10.1111/apt.18354 Sung Noh Hong, Joo Hye Song, Sung Jin Kim, Yoon Ha Park, Chang Wan Choi, Ji Eun Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-11-18 , DOI: 10.1111/apt.18354 Sung Noh Hong, Joo Hye Song, Sung Jin Kim, Yoon Ha Park, Chang Wan Choi, Ji Eun Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
![]() |
Predose trough concentrations (Ctrough) of intravenous infliximab (IV-IFX) during maintenance therapy are associated with therapeutic outcomes in patients with Crohn's disease (CD). A subcutaneous formulation of infliximab (SC-IFX) has shown high Ctrough values due to its favourable pharmacokinetics.
中文翻译:
克罗恩病患者粘膜和透壁愈合的皮下英夫利昔单抗浓度阈值
维持治疗期间静脉注射英夫利昔单抗 (IV-IFX) 的给药前谷浓度 (C谷) 与克罗恩病 (CD) 患者的治疗结果相关。英夫利昔单抗 (SC-IFX) 的皮下制剂由于其良好的药代动力学而显示出高 C谷值。
更新日期:2024-11-18
中文翻译:

克罗恩病患者粘膜和透壁愈合的皮下英夫利昔单抗浓度阈值
维持治疗期间静脉注射英夫利昔单抗 (IV-IFX) 的给药前谷浓度 (C谷) 与克罗恩病 (CD) 患者的治疗结果相关。英夫利昔单抗 (SC-IFX) 的皮下制剂由于其良好的药代动力学而显示出高 C谷值。